Halozyme Therapeutics, Inc. · NASDAQ:HALO

Torley Helen sold 50,000 Halozyme Therapeutics, Inc. shares (Form 4)

Traded May 11 to May 13, 2026 · Filed May 13, 2026

From May 11 to May 13, 2026, Torley Helen (Director, PRESIDENT AND CEO) sold 50,000 Halozyme Therapeutics, Inc. shares at an average US$68.68 for US$3.43M under a trading plan, leaving 767,780 shares. Filed May 13, 2026 (Form 4).

Sold
50,000 shares
Price
US$68.68 average (US$64.63 to US$73.12)
Value
US$3.43M
Holding after
767,780 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Director, PRESIDENT AND CEO

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 11, 2026Common StockOption exercise20,000US$12.07787,780Direct
May 11, 2026Common StockSale9,725US$64.63778,055Direct
May 11, 2026Common StockSale3,575US$65.46774,480Direct
May 11, 2026Common StockSale6,700US$66.33767,780Direct
May 12, 2026Common StockOption exercise20,000US$12.07787,780Direct
May 12, 2026Common StockSale100US$67.85787,680Direct
May 12, 2026Common StockSale1,398US$70.29786,282Direct
May 12, 2026Common StockSale9,802US$71.37776,480Direct
May 12, 2026Common StockSale5,900US$72.15770,580Direct
May 12, 2026Common StockSale2,800US$73.12767,780Direct
May 13, 2026Common StockOption exercise10,000US$12.07777,780Direct
May 13, 2026Common StockSale2,100US$68.10775,680Direct
May 13, 2026Common StockSale3,350US$68.88772,330Direct
May 13, 2026Common StockSale3,950US$69.79768,380Direct
May 13, 2026Common StockSale600US$70.81767,780Direct

Source

View original at SEC

Related